News and Releases

TitleCategoriesDatecategories_hfilter
iCo Therapeutics Inc. Provides an Update Regarding Oral Amphotericin Study, Marketing and Partnering Activities2019October 28, 20192019
iCo Therapeutics Inc. Provides a Corporate Update2019October 22, 20192019
iCo Therapeutics Announces Second Quarter 20192019August 28, 20192019
iCo Therapeutics Inc. Announces the Issuance of 41,200,000 Units Pursuant to its Non-Brokered Private Placement2019August 19, 20192019
iCo Therapeutics Provides Corporate Update2019August 6, 20192019
iCo Therapeutics Announces AGM Voting Results2019June 28, 20192019
iCo Therapeutics Announces First Quarter 2019 Financial Results2019May 30, 20192019
iCo Therapeutics Announces 2018 Year End Financial2019April 30, 20192019
iCo Therapeutics Inc. Announces the Issuance of 3,600,000 Units Pursuant to its Non-Brokered Private Placement2019March 5, 20192019
iCo Therapeutics Inc. Announces the Issuance of 14,400,000 Units Pursuant to its C$1,250,000 Non-Brokered Private Placement2019February 25, 20192019
iCo Therapeutics Inc. Announces Notice of Termination of Sub License for Bertilimumab (iCo-008)2019February 19, 20192019
iCo Therapeutics Inc. Announces Upsizing of Non-Brokered Private Placement to $1,250,000 CDN2019February 19, 20192019
iCo Therapeutics Inc. Announces the Issuance of 4,000,000 Units Pursuant to its C$750,000 Non-Brokered Private Placement2019February 11, 20192019
iCo Therapeutics Inc. Announces Non-Brokered Private Placement to Raise C$750,0002019February 7, 20192019
iCo Therapeutics Inc. Announces Non-Brokered Private Placement to Raise C$750,0002019January 31, 20192019
iCo Therapeutics Announces Third Quarter 2018 Financial Results And Corporate Update2018November 29, 20182018
iCo Therapeutics Provides Corporate Update, Including Drug Supply for Next Oral Amphotericin B Efficacy Study2018November 15, 20182018
iCo Therapeutics Announces Oral Amphotericin B Clinical Advisory Board2018October 23, 20182018
iCo Therapeutics Provides Corporate Update2018October 2, 20182018
iCo Therapeutics Announces Additional Positive Pharmacokinetic Results and Presentation at Global Investment Conference2018September 6, 20182018
iCo Therapeutics Announces Second Quarter 2018 Financial Results And Corporate Update2018August 29, 20182018
iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials – Phase 1 Oral Amphotericin B2018July 16, 20182018
iCo Therapeutics Announces Positive Clinical Outcome – Primary Endpoint Met in Phase 1 Oral Amphotericin B Study2018June 27, 20182018
iCo Therapeutics Provides Corporate Update, Announces Completion of Phase 1 Recruitment2018June 20, 20182018
iCo Therapeutics Announces First Quarter 2018 Financial Results And Update On Phase 1 Clinical Trial2018May 30, 20182018
iCo Therapeutics Announces Year End 2017 Financial Results2018April 24, 20182018
iCo Therapeutics Announces Major Milestone – Dosing of First Patient for its Oral Amphotericin B Phase 1 Clinical Study2018April 18, 20182018
iCo Therapeutics Announces Third Quarter 2017 Financial Results2017November 28, 20172017
iCo Therapeutics Announces Ethics Approval for its Oral Amphotericin B Phase 1 Clinical Study2017November 22, 20172017
iCo Therapeutics Announces Upcoming Presentations and Meetings2017September 7, 20172017
iCo Therapeutics Announces Second Quarter 2017 Financial Results2017August 29, 20172017
iCo Therapeutics Inc. Approves Advance Notice Policy2017August 4, 20172017
iCo Therapeutics Announces Election of Directors2017June 30, 20172017
iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset2017June 15, 20172017
iCo Therapeutics Announces Positive Oral Amphotericin Study2017June 12, 20172017
iCo Therapeutics Announces First Quarter 2017 Financial Results2017May 24, 20172017
iCo Therapeutics Announces Year End 2016 Financial Results2017April 19, 20172017
iCo Therapeutics Inc. Announces No Material Change2017March 13, 20172017
CLARIFICATION iCo Therapeutics Announces Positive Study Results and Significant Advances related to Oral Amphotericin B Program2016November 28, 20162016
iCo Therapeutics Announces Third Quarter 2016 Financial Results2016November 24, 20162016
iCo Therapeutics Announces World Wide Exclusive Option and EU License Rights with Laboratorios SALVAT for Novel Glaucoma Asset2016November 15, 20162016
iCo Therapeutics Announces Second Quarter 2016 Financial Results2016August 19, 20162016
iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders2016June 27, 20162016
iCo Therapeutics Announces Year End 2015 Financial Results2016April 14, 20162016
iCo Therapeutics Inc. Announces Grant of Stock Options and Recent CEO Share Purchases2016February 17, 20162016
iCo Strategic Reorganization2016January 18, 20162016
iCo Therapeutics Announces Changes to Board of Directors2015December 24, 20152015
iCo Therapeutics Announces Third Quarter 2015 Financial Results2015November 24, 20152015
iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program2015October 26, 20152015
iCo Therapeutics Announces Second Quarter 2015 Financial Results2015August 26, 20152015
iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders2015June 26, 20152015
iCo Therapeutics Announces First Quarter 2015 Financial Results2015May 28, 20152015
iCo Therapeutics Announces Year End 2014 Financial Results2015April 27, 20152015
iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update2014November 28, 20142014
iCo Therapeutics Announces Oral Amphotericin Presentations at AAPS2014November 4, 20142014
iCo Therapeutics Announces Advancement of Oral Amphotericin B Program2014October 22, 20142014
iCo Therapeutics Announces Second Quarter 2014 Financial Results2014August 29, 20142014
iCo Therapeutics Announces Positive Oral Amphotericin B Study Results2014August 19, 20142014
iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders2014June 30, 20142014
iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema2014June 9, 20142014
iCo Therapeutics Announces First Quarter 2014 Financial Results2014May 29, 20142014
iCo Therapeutics Announces Poster Presentation at ARVO2014April 29, 20142014
iCo Therapeutics Announces Year End 2013 Financial Results2014April 24, 20142014
iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study2014March 5, 20142014
iCo Therapeutics Announces DTC Approval2014February 25, 20142014
iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing2014January 27, 20142014
iCo Therapeutics Inc. Announces C$6.75 Million Equity Financing2014January 22, 20142014
iCo Therapeutics Inc. Announces Overnight Marketed Equity Offering2014January 21, 20142014
iCo Therapeutics Begins Trading on the OTCQX Marketplace2013December 20, 20132013
iCo Therapeutics Announces Program and Intellectual Property Advancements for Oral Amphotericin B2013December 12, 20132013
iCo Therapeutics To Present At Jefferies Ophthalmic Therapeutic Summit2013December 5, 20132013
iCo Therapeutics Announces Third Quarter 2013 Financial Results2013November 27, 20132013
iCo Therapeutics to Present at the 6th Annual LD MICRO2013November 21, 20132013
iCo Therapeutics Announces Warrant Exercise2013November 13, 20132013
iCo Therapeutics to Present at the Ophthalmology Innovation Summit2013November 7, 20132013
iCo Therapeutics Grants Options to a Director2013September 5, 20132013
iCo Therapeutics to Present at the Rodman & Renshaw 2013 Annual Global Investment Conference2013September 4, 20132013
iCo Therapeutics Announces Second Quarter 2013 Financial Results2013August 26, 20132013
iCo Therapeutics Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema2013June 18, 20132013
iCo Therapeutics Announces First Quarter 2013 Financial Results2013May 29, 20132013
iCo Therapeutics Announces Director Election Results from its Annual General Meeting of Shareholders2013May 24, 20132013
iCo Therapeutics Closes $3.4 Million Financing2013May 21, 20132013
iCo Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Conference2013May 15, 20132013
iCo Therapeutics to Raise $3.2 Million2013May 10, 20132013
iCo Therapeutics Announces Overnight Marketed Equity Offering2013May 9, 20132013
iCo Therapeutics Announces Year End 2012 Financial Results2013April 25, 20132013
iCo Therapeutics Ranked Number One in Technology & Life Sciences on 2013 TSX Venture 502013February 14, 20132013
iCo Therapeutics to Present at the 15th Annual BIO CEO & Investor Conference2013February 5, 20132013
iCo Therapeutics Grants Options to Directors, Officers and Employees2013January 22, 20132013
iCo Therapeutics Announces Positive iCo-007 Phase 2 Clinical Update2013January 3, 20132013
iCo Therapeutics Announces Third Quarter 2012 Financial Results2012November 29, 20122012
iCo Therapeutics’ Oral Amphotericin B Delivery System to be Presented at AAPS with Updated Patent Position2012October 12, 20122012
iCo Therapeutics to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference2012September 4, 20122012
iCo Therapeutics Announces Second Quarter 2012 Financial Results2012August 29, 20122012
iCo Therapeutics Closes $2.55 Million Financing2012July 13, 20122012
iCo Therapeutics to Raise $2.55 Million2012July 5, 20122012
iCo Therapeutics Announces Overnight Marketed Equity Offering2012July 4, 20122012
iCo Therapeutics receives funding from the Government of Canada for the pre-clinical and clinical development of its Oral Amphotericin B Delivery System for the treatment of HIV/AIDS2012May 31, 20122012
iCo Therapeutics Announces First Quarter 2012 Financial Results2012May 30, 20122012
iCo Therapeutics Announces Year End 2011 Financial Results2012April 13, 20122012
iCo Therapeutics and JDRF Team Up to Support Phase II Clinical Trial iDEAL for Diabetic Macular Edema2012March 28, 20122012
iCo Therapeutics CEO to Present at Retinal Physician Symposium 20122012March 27, 20122012
iCo Therapeutics Appoints Douglas Janzen to Board of Directors2012March 5, 20122012
iCo Therapeutics Retains Crescendo Communications2012January 17, 20122012
iCo Therapeutics Announces Execution of Equity Line Facility Agreement2011December 4, 20112011
iCo Therapeutics Announces Third Quarter 2011 Financial Results2011November 18, 20112011
iCo Therapeutics Closes $1,115,000 Non-Brokered Private Placement2011November 2, 20112011
iCo Therapeutics Oral Amphotericin B Delivery System to be Presented at AAPS2011October 24, 20112011
iCo Therapeutics CEO to Present at the Ophthalmology Innovation Summit2011October 20, 20112011
iCo Therapeutics Grants Options to Directors, Officers and Employees2011September 27, 20112011
iCo Therapeutics and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema2011September 26, 20112011
iCo Therapeutics CEO to Present & Act as Co-Chairperson at the 4th Annual Drug Repositioning and Pipeline Enhancement Conference2011September 13, 20112011
iCo Therapeutics CEO to Present & Act as Co-Chairperson at the 4th Annual Drug Repositioning and Pipeline Enhancement Conference2011September 13, 20112011
iCo Therapeutics Announces Second Quarter 2011 Financial Results2011August 29, 20112011
iCo Therapeutics Announces Key iCo-007 Clinical Development Milestone2011August 15, 20112011
iCo Therapeutics Announces Resignation of John Clement, Chief Technology and Development Officer and Director2011July 22, 20112011
iCo Therapeutics Engages The Equicom Group2011July 19, 20112011
iCo Therapeutics CMO to Present at The Drug Repositioning Conference2011July 12, 20112011
iCo Therapeutics Announces First Quarter 2011 Financial Results2011June 29, 20112011
iCo Therapeutics Executes Bertilimumab License with Immune Pharmaceuticals2011June 24, 20112011
iCo Therapeutics CEO to Present & Participate in Panel at BioFinance 20112011May 31, 20112011
iCo Therapeutics Inc. Engages Ora for Ophthalmic Clinical & Regulatory Guidance2011May 13, 20112011
iCo Therapeutics Announces Year-End 2010 Financial Results2011April 29, 20112011
iCo Therapeutics Inc. Secures $10 Million Equity Line Facility2011April 14, 20112011
iCo Therapeutics Inc. iCo-007 Program to be Presented & CEO to Sit on Panel at Retinal Physician Symposium 20112011February 23, 20112011
iCo Therapeutics Inc. Completes iCo-007 Phase 2 Clinical Supply Manufacturing2011February 22, 20112011
iCo Therapeutics Extends Investor Relations Engagement with The Trout Group2010December 24, 20102010
iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US$33 Million Plus Royalties2010December 8, 20102010
iCo Therapeutics Reports Third Quarter 2010 Financial Results2010November 26, 20102010
iCo Therapeutics Selected as Canada’s Top 10TM Competition Winner2010October 13, 20102010
iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status2010September 29, 20102010
iCo Therapeutics Appoints Infectious Disease Experts to Scientific Advisory Board2010September 22, 20102010
iCo Therapeutics Announces Second Quarter 2010 Financial Results2010August 27, 20102010
iCo Therapeutics Inc. receives Health Canada Clearance to Conduct Phase II DME Trial with iCo-0072010July 26, 20102010
iCo Therapeutics Inc. enters into Investor Relations Engagements with The Trout Group and Sector Speak2010May 28, 20102010
iCo Therapeutics Announces First Quarter 2010 Financial Results2010May 26, 20102010
iCo Therapeutics Inc. enters into Technology Transfer Agreement with Isis Pharmaceuticals, Inc. for iCo-0072010May 25, 20102010
iCo Therapeutics iCo-007 Phase I Clinical Trial Meets Primary Endpoint2010May 17, 20102010
iCo Therapeutics Announces Year-End 2010 Financial Results2011April 29, 20102011
iCo Therapeutics Announces Year-End 2009 Financial Results2010April 29, 20102010
iCo Therapeutics Inc. engages Susan Koppy to spearhead iCo-007 out-licensing2010April 28, 20102010
iCo-007 for Diffuse Diabetic Macular Edema to be Presented at Retinal Physician Symposium 20102010April 22, 20102010
iCo Therapeutics Inc. Secures $10 Million Equity Line Facility2011April 14, 20102011
iCo Therapeutics Inc. Recognized by BIOTECanada with Gold Leaf Award2010April 12, 20102010
iCo Therapeutics Inc. iCo-007 Program to be Presented & CEO to Sit on Panel at Retinal Physician Symposium 20112011February 23, 20102011
iCo-007 for Diabetic Macular Edema to be Presented at Angiogenesis 2010: Clinical Trials2010February 19, 20102010
iCo Therapeutics Announces Exercise of Warrants2010February 10, 20102010
iCo Therapeutics Grants Options to Directors, Officers and Employees2009December 30, 20092009
iCo Therapeutics Provides Phase 1 DME Clinical Trial Update and Phase 2 Trial Guidance2009December 11, 20092009
iCo Therapeutics iCo-007 Overview to be Presented at the 8th International Symposium on Ocular Pharmacology and Therapeutics2009December 3, 20092009
iCo Therapeutics Q3 2009 Financial Results2009November 26, 20092009
iCo Therapeutics Completes Final Tranche of $4,000,000 Brokered Private Placement2009November 20, 20092009
iCo Therapeutics Completes First Tranche of Brokered Private Placement2009October 30, 20092009
iCo Therapeutics Announces $4,000,000 Brokered Private Placement2009October 20, 20092009
iCo Therapeutics Signs Collaboration Agreement with The Consortium for Parasitic Drug Development2009September 24, 20092009
iCo Therapeutics Q2 2009 Financial Results2009August 21, 20092009
iCo Therapeutics Appoints Infectious Disease MD to Scientific Advisory Board2009July 21, 20092009
iCo Therapeutics Closes Non-Brokered Private Placement2009July 16, 20092009
iCo Therapeutics Diabetic Macular Edema Clinical Trial Update2009July 7, 20092009
iCo Therapeutics Publishes Review of Diabetic Retinopathy Treatment2009July 2, 20092009
iCo Therapeutics Positive Oral Amphotericin B Data Published in the Journal of Infectious Diseases2009June 25, 20092009
Shareholders Approve All Resolutions at iCo Therapeutics Annual General Meeting2009June 8, 20092009
iCo Therapeutics Q1 2009 Financial Results2009May 29, 20092009
iCo Therapeutics Year-End 2008 Financial Results2009April 30, 20092009
iCo Therapeutics to Present at BioFinance 20092009April 29, 20092009
iCo Therapeutics Oral Anti-Parasitic Drug to be Presented at Global Health Symposia2009March 23, 20092009
iCo Therapeutics iCo-007 Second Cohort Results to be Presented at Cleveland Clinic Ocular Conference2009March 17, 20092009
iCo Therapeutics Grants Options to New Directors2009February 20, 20092009
iCo Therapeutics iCo-007 Results to be Presented at Prestigious Ocular Conference2009February 19, 20092009
iCo Therapeutics Oral Amphotericin B Published in Leading Journal2009February 18, 20092009
iCo Therapeutics Closes $1.3 Million Private Placement2009February 9, 20092009
iCo Therapeutics Closes First Tranche of Non-Brokered Private Placement2009January 30, 20092009
iCo Therapeutics Oral Amphotericin B Poster at AAPS2008November 18, 20082008
iCo Therapeutics Third Quarter Financial Results2008November 17, 20082008
iCo Therapeutics Oral Amphotericin B Effective Against Visceral Leishmaniasis2008November 7, 20082008
iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Pharmacokinetic Results2008October 9, 20082008
iCo Therapeutics Selected as Canada’s Top 10TM Competition Winner2008October 1, 20082008
iCo Therapeutics to Present at BioContact Québec2008September 29, 20082008
iCo Therapeutics Provides Interim Trial Results (Diffuse Diabetic Macular Edema)2008September 22, 20082008
iCo Therapeutics Outlines Steps to First iCo-009 Human Clinical Trial2008September 4, 20082008
iCo Therapeutics Second Quarter Financial Results2008August 28, 20082008
iCo Therapeutics Appoints Mr. Noel Hall and Dr. Christian Fibiger to Board2008July 8, 20082008
iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B) Preclinical Results2008June 26, 20082008
iCo Therapeutics Closes $1,140,450 Financing2008June 9, 20082008
iCo Therapeutics Announces $1,140,450 Financing2008June 2, 20082008
iCo Therapeutics First Quarter Financial Results2008May 30, 20082008
iCo Therapeutics Acquires Worldwide Rights to iCo-009 (Oral Amphotericin B)2008May 7, 20082008
iCo Therapeutics to Present at BioFinance 20082008May 5, 20082008
iCo Therapeutics Year-End 2007 Financial Results2008April 28, 20082008
iCo Therapeutics iCo-007 Diabetic Macular Edema Poster Presentation at ARVO2008April 25, 20082008
iCo Therapeutics Announces iCo-009 (Oral Amphotericin B) FDA Meeting2008April 21, 20082008
iCo Therapeutics iCo-009 (Oral Amphotericin B) Published in Leading Drug Delivery Journal2008March 17, 20082008
iCo Therapeutics Provides iCo-008 Phase II Clinical Update2008March 10, 20082008
iCo Therapeutics Announces CMO Invited to Present at International Ocular Conference2008February 27, 20082008
iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Update2008January 21, 20082008
iCo Therapeutics Inc. and Beanstalk Capital Ltd. Announce Completion of Arrangement2007December 31, 20072007
Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement2007October 31, 20072007
Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc.2007October 16, 20072007
Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-0072007October 9, 20072007
iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema2007January 22, 20072007
iCo Therapeutics Announces Licensing Deal2007January 10, 20072007
Cambridge Antibody Tech. licenses monoclonal antibody for treatment of allergy disorders to iCo2007January 8, 20072007